In total, 32.8% of patients were immunocompromised (n = 58/177; ie, with ongoing immunosuppressive therapy or with ongoing chemo-/radio-/corticotherapy, or with hemopathy, metastatic cancer, or HIV+ with CD4 lymphocytes <500/mm3 at inclusion). Here, CD4 is linked to metastatic malignant neoplasm.